Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Inclusion Criteria: * Confirmed diagnosis of locally advanced or metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IIIB, IIIC or IV) that is refractory to standard therapy or for which no curative standard therapy exists. * Measurable disease * Must be eighteen years of age or older * Must meet baseline laboratory requirements * ECOG performance status 0 or 1 * Adults of reproductive potential must agree to use effective contraception or be sterile Exclusion Criteria: * Concurrent therapy with any other investigational agent * Uncontrolled central nervous system metastases * Impaired cardiac function or clinically significant cardiac disease * Received * chemotherapy, targeted therapy or monoclonal antibody therapy ≤4 weeks * biological therapy or immunotherapy (therapeutic or diagnostic) ≤2 weeks * an investigational agent (therapeutic or diagnostic) ≤4 weeks prior to starting study drug or has not recovered from side effects of such therapy * Received any hematopoietic colony-stimulating factor (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin is allowed. * Has undergone major surgery ≤ 2 weeks prior to starting study drug or has not recovered from side effects of such surgery. * Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea, diarrhea, vomiting * Pregnant or breast feeding women * History of another primary malignancy that is currently clinically significant or currently requires active intervention. * Chronic anticoagulation therapy with full strength aspirin, Coumadin, or heparin. * History of thromboembolic or cerebrovascular events within the last 12 months. * History of rectal bleeding, bloody vomit, or spitting up blood within the last 3 months. * Known diagnosis of HIV infection (HIV testing is not mandatory) * Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort and quinidine is prohibited. * Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study-drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, make the patient inappropriate for this study